Items where authors include "Royle, K.-L."

Article

Mehta, D., Cicero, R., Chiecchio, L. et al. (10 more authors) (2024) Risk adapted therapy for newly diagnosed multiple myeloma delivered through local cytogenetic laboratories in a National Clinical Trial: UKMRA RADAR study. eJHaem. ISSN 2688-6146 (In Press)

Collinson, F. orcid.org/0000-0001-6964-6406, Royle, K.-L. orcid.org/0000-0003-0225-1199, Swain, J. orcid.org/0000-0003-2729-3029 et al. (28 more authors) (2024) Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT. Health Technology Assessment, 28 (45). ISSN 1366-5278

Royle, K.-L. orcid.org/0000-0003-0225-1199, Meads, D., Visser-Rogers, J.K. et al. (2 more authors) (2023) How is overall survival assessed in randomised clinical trials in cancer and are subsequent treatment lines considered? A systematic review. Trials, 24. 708. ISSN 1745-6215

Brown, J.E. orcid.org/0000-0003-4960-3032, Royle, K.-L., Gregory, W. et al. (96 more authors) (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24 (3). pp. 213-227. ISSN 1470-2045

Proceedings Paper

Dawkins, B., Gkountouras, G., Meads, D. et al. (21 more authors) (2024) Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07-10 Dec 2024, San Diego, USA. American Society of Hematology , pp. 385-386.

Cook, G., Pawlyn, C., Royle, K.-L. et al. (20 more authors) (2024) IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07 Dec 2024, San Diego, USA. American Society of Hematology , pp. 673-674.